華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION
POTENTIAL ACQUISITION OF INTEREST IN LIER CHEMICAL

This announcement is made by China Resources Pharmaceutical Group Limited (the "**Company**" together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company hereby announces that China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) ("**CR Double-Crane**"), an indirect non-wholly owned subsidiary of the Company, has participated in the public solicitation and bidding process initiated by Sichuan Jiuyuan Investment Holdings Group Co., Ltd. (四川久遠投資控股集團有限公司) ("**Jiuyuan Group**") and Sichuan Huacai Technology Co., Ltd. (四川化材科技有限公司) ("**Huacai Technology**", together with Jiuyuan Group, the "**Sellers**") for the transfer of 188,102,749 shares in aggregate held by the Sellers in Lier Chemical Co., Ltd. (利爾化學股份有限公司) ("**Lier Chemical**", a company listed on the Shenzhen Stock Exchange (stock code: 002258)), representing approximately 23.50% equity interest in Lier Chemical (the "**Potential Acquisition**"). Lier Chemical is principally engaged in the research and development, production and sales of high efficiency, low-toxicity and low-residue safe pesticide ingredients and pesticide formulations. On 15 July 2026, CR Double-Crane received notice from the Sellers that it ranked first among the prospective transferees for the public solicitation and bidding process. As of the date of this announcement, CR Double-Crane did not hold any equity interest in Lier Chemical.

The Group, through CR Double-Crane, has been developing its presence in the synthetic biology sector since 2022, and currently has established seven major technology platforms, with a focus on four key areas, being pharmaceutical ingredient intermediates, health-related novel food products, crop and animal protection (such as pesticides and veterinary drugs), and new materials and new energy. The Company believes that the Potential Acquisition meets the Group's overall strategic plan and will help drive the commercialisation of its synthetic biology pipeline technology products.

The Potential Acquisition is subject to the execution of relevant transaction agreements and the terms and conditions as set forth therein. The Company will comply with the applicable requirements under Chapter 14 of the Listing Rules upon the execution of the relevant transaction agreements as and if required.

As of the date of this announcement, no definitive transaction agreements have been entered into by the Group for the Potential Acquisition. The Potential Acquisition is subject to various factors, including execution of relevant agreements and conditions as set forth therein. Accordingly, the Potential Acquisition may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 15 July 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Cheng Jie and Mr. Liu Changan as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.